Sundar Dheepak, Das Taraprasad, Chhablani Jay, Kumar Atul, Sharma Namrata
Dr. RP Centre for Ophthalmic Sciences, All India Institute of Ophthalmic Sciences, New Delhi, India.
L V Prasad Eye Institute, Kallam Anji Reddy Campus, Hyderabad, India.
Indian J Ophthalmol. 2020 Jun;68(6):1095-1098. doi: 10.4103/ijo.IJO_1602_19.
The aim of this paper is to report the results of an on-line survey to evaluate the practice pattern of Indian retina specialists in administering intravitreal anti-vascular endothelial growth factor injection.
A structured questionnaire on the intravitreal injection (IVI) procedure protocols was sent online to all members of the All India Ophthalmological Society (AIOS) with a request to the retina specialists to respond. A unique link that directed to the web-based questionnaire page allowed a single response only. Participating physicians were masked from each others' responses. The responses were categorized into pre-injection patient preparation, injection aliquoting, injection administration, and post-injection care. The results were compared with similar surveys in Europe, the UK, and the USA.
Response was received from 741 of 1016 (73%) retina specialists (of 16,000 AIOS ophthalmologists). The survey showed: 43.5% evaluated patient's cardiac risk factors, 60% used prophylactic topical antibiotic, 90.9% performed injection under topical anesthesia, 55% aliquoted from the bevacizumab vial at the eye care facility, 66.2% used a single puncture technique, 91.4% injected in the main operating room, 98% wore masks and sterile gloves during the procedure, 96% used lid speculum, and 89.3% advised topical antibiotic after the procedure. Peri procedure antibiotic use, injection in the min operating room, wearing of gloves and mask were higher than practices in other countries.
Ophthalmologists in India practice asepsis in IVI procedure. There is no uniform protocol for aliquoting bevacizumab. Single use bevacizumab vial for exclusive ophthalmic use will further improve the safety of the procedure.
本文旨在报告一项在线调查的结果,以评估印度视网膜专家玻璃体内注射抗血管内皮生长因子的实践模式。
一份关于玻璃体内注射(IVI)程序方案的结构化问卷通过网络发送给全全全印度眼科协会(AIOS)的所有成员,并要求视网膜专家进行回复。一个指向基于网络的问卷页面的唯一链接只允许单次回复。参与的医生彼此看不到对方的回复。回复被分为注射前患者准备、注射分装、注射给药和注射后护理。结果与欧洲、英国和美国的类似调查进行了比较。
1016名视网膜专家(在16000名AIOS眼科医生中)中的741名(73%)回复了调查。调查显示:43.5%的人评估了患者的心脏危险因素,60%的人使用预防性局部抗生素,90.9%的人在局部麻醉下进行注射,55%的人在眼科护理机构从贝伐单抗小瓶中进行分装,66.2%的人使用单穿刺技术,91.4%的人在主手术室进行注射,98%的人在手术过程中佩戴口罩和无菌手套,96%的人使用眼睑撑开器,89.3%的人在术后建议使用局部抗生素。围手术期抗生素的使用、在小手术室进行注射、佩戴手套和口罩的比例高于其他国家的做法。
印度眼科医生在IVI手术中实行无菌操作。对于贝伐单抗的分装没有统一的方案。专供眼科使用的一次性贝伐单抗小瓶将进一步提高手术的安全性。